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Introduction
The Global Alliance against Chronic Respiratory Diseases 
(GARD) is a voluntary network of national and international 
organizations, institutions and agencies led by the World 
Health Organization (WHO), working towards the vision 
of a world where all people breathe freely (1). GARD is 
supporting WHO in successfully implementing the WHO’s 
Global Action Plan for the Prevention and Control of 
Noncommunicable Diseases (NCDs) 2013–2020. The 
GARD report on GARD activities is published on a regular 
basis. Collaboration among GARD countries is critical for 
sharing experiences and providing technical assistance to 
developing countries based on each country’s needs (2). 
The annual GARD meeting is a unique opportunity for 
assembling all of the GARD participants from developed 
and developing countries: European countries, North and 
South American Countries, China, Vietnam as well as 
Eastern Mediterranean, and African countries. Coordinator 
for Management of NCDs in the WHO Department for 
Management of Noncommunicable Diseases, Disability, 
Violence and Injury Prevention (Cherian Varghese) is 
present at this meeting. 
The annual meeting of GARD is a forum for exchanging 
opinions in order to improve care for chronic respiratory 
diseases (CRDs) and to achieve the GARD goal—a world 
where all people breathe freely. Experts—in collaboration 
with WHO—are helping developing countries to achieve 
their projects regarding teaching, research and programming 
for CRD. 
Each year, there is a poster presentation session on 
country activities. Each participant is able to present his/
her country activities that have been achieved since the last 
meeting. This is followed by discussion. 
In this paper, we summarize the posters presented during 
the 11th GARD general meeting. We hope that this will 
give readers of the GARD section an opportunity to learn 
for their countries.
We can find all posters on the link: https://gard-
breathefreely.org/resources-poster/.
United States: the US COPD National Action 
Plan (US-CNAP)
Chronic obstructive pulmonary disease (COPD) is currently 
the fourth leading cause of death in the US and the fourth 
leading cause of disability. In 2010, more than $32 billion 
was spent on COPD-related patient care; and those costs 
are projected to increase to $49 billion by 2020. COPD 
prevalence varies geographically in the US, with several 
pockets of higher prevalence in rural settings. To address 
COPD, the US Congress encouraged the National Institute 
of Health (NIH) “to work with community stakeholders 
and other federal agencies, including the CDC, to develop 
a national action plan. The NHLBI/NIH engaged the 
COPD community at large, including patients and their 
families, health care providers, academia, and industry to 
deliver the first US-CNAP. The US-CNAP has five goals: (I) 
empower people with COPD, their families, and caregivers 
to recognize and reduce the burden of COPD; (II) improve 
the prevention, diagnosis, treatment, and management of 
COPD by improving the quality of care delivered across 
the health care continuum; (III) collect, analyze, report, 
and disseminate COPD-related public health data that 
drive change and track progress; (IV) increase and sustain 
research to better understand the prevention, pathogenesis, 
diagnosis, treatment, and management of COPD; and 
(V) translate national policy, educational, and program 
recommendations into research and public health care 
actions. The involvement of the entire COPD community 
is critical to the plan implementation. A variety of tools are 
available at www.COPD.nih.gov (3-7).
Canada: the Ontario Asthma Surveillance 
Information System (OASIS)
The OASIS funded by the Ontario Ministry of Health 
(MoH) and Long-term Care, is a population-based 
asthma registry in Ontario, Canada. Established in 2003, 
OASIS follows over 2 million Ontarians of all ages with 
physician-diagnosed asthma who have been identified from 
provincial health administrative databases using a validated 
algorithm. The objective of OASIS is to provide ongoing 
asthma surveillance statistics, including asthma incidence, 
prevalence, measures of asthma-related morbidity, mortality, 
health services use, and provider practice patterns. The 
assessments of asthma health made possible by surveillance 
serve as a benchmark for monitoring changes in diagnosis, 
treatment and management in asthma across geographical 
regions and in different sub-groups. Furthermore, OASIS 
is also a rich data source that serves as a platform for novel 
epidemiological research. In recent years, the OASIS team 
has deconstructed the role of comorbidities in asthma, 
established indicators for quality of asthma care, and 
investigated the role of air pollution as a risk factor for 
the development of concurrent respiratory conditions in 
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those with asthma (5). The OASIS assists policymakers 
and stakeholders to make evidence-informed decisions on 
targeting health programs to at-risk populations and on 
developing structures to support effective, efficient and 
accessible asthma care (8-12).
Mozambique: morbidity, efforts and needs
Mozambique owns 27.978 million habitants with a life 
expectancy of 53.5 years. Sixty percent of the population 
live in rural areas. The burden of communicable diseases is 
high but we begin to observe a rising in NCDs since 2000. 
Prevalence of asthma in children between 6–7/13–14 years 
is 13.3%. In national hospitals, adult asthma is the first 
cause of morbidity at 0.5%, but the data for COPD is still 
unknown. Currently, the main noted constraints include 
limited access to health services, primary health center 
overloaded for infection diseases (CD) neglecting the other 
NCDs, the difficulty for physicians to diagnose CRDs, lack 
of spirometers and access to essential medicines. 
Our achievements include: Guidelines of Bronchial Asthma 
in Adults was elaborated; the Second STEPwise Approach to 
Surveillance 2014/2015 was finished; WHO Framework 
Convention on Tobacco Control (FCTC) was rectified 
and the ARELP (Respiratory Association of Portuguese 
Language) conference on CRDs and Tuberculosis was held.
Research was conducted to study lung function 
impairment in patients after TB treatment and to study 
the burden of respiratory diseases in the emergency 
departments of four hospitals. 
To stop the growth of CRDs, we need to increase 
primary care physicians’ ability to diagnose the prevalent 
CRDs and provide spirometeres/essential medicines, and 
show CRD prevalence evidence to make CRDs “visible” to 
change policy in Mozambique (13-18). 
Portugal: Portuguese National Programme for 
Respiratory Diseases (PNPRD)
CRDs is a priority for Portugal since 2000, evidenced by 
the PNPRD by the Ministry of Health (MoH) under the 
scope of High Directorate of Health (2012–2020) and 
aligned with WHO strategies and GARD. The prevalence 
of asthma is estimated at 11.0% for children and 5.2% for 
adults, and the prevalence is 14.2% for COPD (≥40 y). 
The aim of GARD activities in Portugal is to reduce the 
CRD burden by epidemiological surveillance, prevention, 
early diagnosis, treatment, monitoring, legislation proposal, 
communication and social mobilization, promotion of 
literacy and collaboration with national and international 
partners. 
The intervention in PNPRD priority areas at high 
prevalence of asthma, COPD and sleep apnea syndrome 
includes primary and secondary care by implementing 
guidelines, electronic prescription, implementation of a 
national spirometry network, free influenza vaccination 
in specific groups, accessibility to smoking cessation, 
respiratory rehabilitation and reimbursement for medicines 
or home respiratory care in national health service (NHS). 
For cystic fibrosis (high differentiation area), the goals are 
neonatal screening, free treatment in reference centers and 
total reimbursement for home respiratory care. Results are 
published in annual reports.
Portugal is one of the European countries with the 
lowest hospitalizations for asthma and COPD and better-
standardized mortality rate (0.1 and 1.3 respectively per 
100,000 persons aged below 65). From 2011 to 2016, 
early diagnoses of asthma and COPD in primary care 
are increasing (>100%) and the variation of the sales of 
respiratory drugs shows that patients are better treated 
(salbutamol decreased by 15%; bronchodilators and inhaled 
corticosteroids increased by >25%) (19-23).
Brazil: morbidity, management and resources
The achievements achieved in Brazil include as follows: 
the Asthma and COPD guidelines launched by the MoH 
in 2010; asthma hospitalization reduced by 66% in the 
past 10 years; prevalence of tobacco smoking reduced 
from 33% to 15% in the past 25 years; less underdiagnosis 
of asthma among adolescents, i.e., an increase in the 
proportion of diagnosed asthma and an reduction in 
symptom prevalence last year; COPD diagnoses increased 
by 18%; asthma and COPD protocols and/or management 
programs implemented at state/province level; essential 
asthma medicines (beclomethasone-pMDI and albuterol-
pMDI) available for free across the country; ICS+LABA 
combination, tiotropium and home oxygen therapy now 
provided by some state/province health authority; a special 
program on severe/difficult-to-treat and severe-resistant-
to-treatment asthma managed by several tertiary referral 
centers (universities and other institutions) across the 
country; spirometry available although only at referral 
institutions (not at primary health care facilities) across 
the country; and implementation of outreach educational 
programs including the matrix support collaborative care 
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and Practical Approach to Care Kit (PACK).
The main issue is to get the MoH formally committed 
with GARD/GINA/ARIA activities and initiatives. Brazil 
urgently needs a wide public health policy to address CRDs, 
where the role of National, State and Municipal Health 
Authorities would be clearly defined (24-28). 
Latin America: programs and proposals 
In Latin America, COPD affects 10% to 20% of the 
population, while asthma prevalence is more than 30% 
in some countries of the region. In GARD 2017 annual 
meeting held in Brussels, joint actions as well as regional 
representations were evidenced as real unmet needs.
There are several successful programs on morbidity 
and mortality control of these diseases, like Programa para 
controle da Asma e da Rinite Alérgica (ProAR) and Programa 
Infantil de Prevenção de Asma (PIPA) in Brazil, and Proyecto de 
Prevención en Asma, Prevención en Alergia (PAPA) in México. 
Among others, Practical Approach to Care Kit (PACK) and 
an ARIA program involving the Integrated Care Pathways 
in Airways are on their way in Brazil and Uruguay, and an 
asthma program in the elderly in Argentina.
Participants from the region supported proposals of Latin 
American Society of Allergy, Asthma and Immunology 
(SLAAI): (I) to contribute on diffusion and knowledge of 
CRDs magnitude and risk factors; (II) to identify successful 
programs in Latin America to be replicated in the region; 
(III) to generate strategic alliances in order to strengthen 
joint actions. 
Calling to members of SLAAI for a joint meeting 
with GARD representatives and applying for GARD 
membership were established as next steps in near future 
(29-33).
Syria: collaborated contributions and 
involvements of Tishreen University, Ministry of 
Higher Education, and Ministry of Health
On the basis of a multicenter national GARD-WHO 
Survey on prevalence and risk factors of CRDs and 
co-morbidities at primary care level lead by Tishreen 
University in collaboration with Syrian MoH, the National 
Center for Research on Chronic Respiratory Diseases and 
Comorbidities, Tishreen University, Ministry of Higher 
Education (MOHE) in Syria, collaborating with GARD 
and WHO, Regional Office for the Eastern Mediterranean 
(EMRO), was initiated. However, WHO program is rather 
emergency oriented during the war. 
This national center edited a book entitled “Technical 
Guide for Management of Chronic Respiratory Diseases in 
Primary Care, Emergency Rooms and General Medicine 
Outpatient Clinics in Public Hospitals”, which was printed in 
2016, and distributed to primary care doctors, and residents 
in general hospitals in Syria, thanks to Ms. Elizabeth Hoff, 
WHO representative in Syria. 
This guidebook includes: (I) guidelines for management 
of asthma and COPD in outpatients clinics of general 
secondary care hospitals; (II) audits for evaluation of 
practice based on GINA (www.ginasthma.org) and GOLD 
(www.goldcopd.org); (III) a book chapter on the essential 
facts that need to be known for primary care about asthma, 
COPD and allergic rhinitis, such as early diagnosis, patient 
education, smoking cessation, how to use inhalers and 
spacers, and safety of inhaled corticosteroids; (IV) how 
spacers could replace Nebulizer, peak flow, and how to 
interpret spirometry; and (V) algorithms protocols of 
WHO-PEN (translated to Arabic and adapted to Syria) for 
use in primary care centers. 
This book was adopted by Syrian MoH and MOHE for 
training and programs. A committee for CRDs was established 
afterwards, managed by the MOH Department of NCD in 
collaboration with Tishreen University Center and WHO 
country office. Standardized power point presentations for 
training of residents, GPs, pharmacists and nurses, as well as 
educational brochures for patients were prepared and uploaded 
on the MOH website. Training on CRD and spirometry for 
primary care physicians are being continuously supported by 
WHO country office during the war.
Moreover, a survey was conducted to track under-
diagnosed and uncontrolled asthma in shelters during the 
Syrian crisis. This was a GARD survey in collaboration 
between GARD, Syria and GARD AOSIS (Asthma Ontario 
Surveillance Information System).
Evidences showed that poor shelter or dwelling 
conditions may lead to deterioration of asthma control. 
Our research explored the characteristics of asthmatics 
living in the shelters in Syria, and estimated the prevalence 
of under-diagnosed asthma among refugees displaced 
in Syria during the conflict. The research site is the Al-
Herjalleh shelter near Damascus, with 850 dwellers. The 
results showed that:
 Asthma was uncontrolled in all subjects. Only 4% 
used inhaled corticosteroids, compared to 30% 
before the war.
 Forty-four percent of non-diagnosed asthmatics 
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in the shelter replied yes to the question “Do 
you wake up by attacks of cough, wheezing and 
breathlessness”, suggesting underlying undiagnosed 
asthma that could have been concealed by these 
poorer environmental and psychological conditions 
although new onset asthma cannot be excluded. 
 Lung functions: FEV1 was lower than 80% 
predicted before bronchodilators in 61% and after 
bronchodilators in 7% of the respondents who 
replied yes to the above question. 
 Post-traumatic stress disorder was noted in 35%, 
and allergic rhinitis in 57% of the respondents who 
replied yes to the above question.
An ad hoc help by medications was initiated. A national 
program for asthma and COPD in shelters and conflict 
zones is under consideration to be integrated with MOH-
WHO and Red Cross-Red Crescent dispensaries and 
mobile clinics (34-37).
Vietnam: expanding the network of Asthma and 
COPD Outpatient Care Units (ACOCUs)
Asthma and COPD are two conditions with high prevalence 
and associated with enormous economic burden in Vietnam. 
The estimated numbers of Vietnamese asthmatic and 
COPD patients are around 7.2 million. 
Although asthma and COPD are included in National 
Program against Non-communicable Diseases from 2015 to 
2025 in Vietnam, spirometry and asthma-COPD drugs are 
not available at all province and district hospitals. 
In collaboration with national and international 
organizations on development and expansion of ACOCU 
network, several interventions were conducted during 
2000 and 2017. These included organizing workshops 
regarding management of asthma and COPD, setting up 
new ACOCUs and upgrading the capabilities of the current 
ones, improving the screening and management programs, 
and meeting with medical insurance organization.
A network of 161 ACOCUs has been built since 2000. 
Many future activities are planned to address the remaining 
challenges. These include building and upgrading more 
units to achieve optimal management, having a quality 
control group from National Program, and conducting 
a national study for reference values of spirometric 
parameters for Vietnamese people.
In conclusion, ACOCUs are feasible, sustainable and 
expandable as it meets the needs of any communities (38).
Turkey: achievements of a national control 
program and action plan for CRD
GARD Turkey is a national control program and action 
plan on chronic airway diseases (asthma and COPD) that 
involves the Turkish MoH and Turkish Thoracic Society 
(a non-governmental organization) with 64 collaborating 
parties. This program is integrated with other NCD 
national programs such as cardiovascular diseases, obesity 
and tobacco control.
To evaluate public awareness on COPD and asthma, 
a questionnaire was completed by 8,342 people and 680 
primary care physicians (3). Turkish Statistical Institute 
randomly selected 680 doctors to evaluate primary care 
awareness. The total of 1,817 and 1,788 primary health 
care physicians attended the asthma and COPD face to face 
education, respectively. Results of those studies are in the 
references.
Meetings on COPD, asthma and pulmonary rehabilitation 
were held, attended by 42,095, 34,789 and 9,020 health-
care workers and 482035, 414024 and 79768 community 
members, respectively. 160 press conferences, 356 radio-
TV speeches, 1,738 news broadcasts, delivery of 1,552,320 
printed handouts, distribution of 6,259 videos, 90,052 tree 
planting sessions (GARD forests), 2,114 stand shows, and 
85,691 spirometry measurements were carried out.
GARD Turkey project has been accepted as a two-
starred reference site for the European Parliament Initiative 
European Innovation for Active and Healthy Aging.
In the future, new online data entry and education 
program for all NCDs will start. We have started ‘Allergy 
Dairy’ by MACVIA ARIA. Accreditation of spirometry 
laboratories will start next year (39-41).
France: ARIA’s care pathways implementing 
emerging technologies for predictive medicine 
in rhinitis and asthma across the life cycle
The initiative Allergic Rhinitis and Its Impact on Asthma 
(ARIA) commenced during a WHO workshop in 1999. 
The initial goals of ARIA were: (I) to propose a new allergic 
rhinitis classification; (II) to promote the concept of multi-
morbidity in asthma and rhinitis, and (III) to develop 
guidelines with all stakeholders that could be used globally 
for all countries and populations.
ARIA is disseminated and implemented in over 70 
countries globally. Currently, a new ARIA initiative has been 
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developed. This initiative, the MASK (MACVIA–ARIA 
Sentinel Network), is an example of a Good Practice focusing 
on the implementation of multi-sectoral care pathways 
for individualized and predictive medicine using emerging 
technologies with real life data in rhinitis and asthma multi-
morbidity by a multidisciplinary group and by patients 
themselves. A mobile phone application for Android or IOS 
(MeDALL) is available in 20 countries and 15 languages. 
It uses a visual analogue scale to assess symptom control 
and work productivity as well as a clinical decision support 
system. It is associated with an inter-operable tablet for 
physicians and other health care professionals.
The scaling up strategy uses the recommendations of the 
European Innovation Partnership on Active and Healthy 
Ageing.
The aim of the novel ARIA approach is to provide an 
active and healthy life to rhinitis sufferers, whatever their 
age, sex or socioeconomic status, in order to reduce health 
and social inequalities incurred by the disease (42-46).
Czech: dedications of Czech Alliance against 
Chronic Respiratory Diseases (ČARO)
ČARO is the country partner of GARD in the Czech 
Republic. It was established in 1997 and since the beginning 
it has integrated 20 members—medical, patient and other 
non-governmental organizations. In 2017, ČARO was 
involved in CRD prevention, anti-smoking campaign, 
epidemiological studies on CRD, and management of 
highly specialized centers. ČARO provided open space 
spirometry measurements, press conferences and meetings 
with media in Prague (on TB Day, Asthma Day, COPD 
Day, and No Tobacco Day). ČARO organized meetings 
of experts and patients. A lecture cycle was launched for 
patients with lung diseases and their family members in 
Olomouc hospital. These patients were gathering in ČOPN 
(Czech Civic Association against Pulmonary Disease). 
A lecture day on the World COPD Day was organized 
in Prague with a program aimed at doctors, nurses and 
also accessible to patients and the general public. ČARO 
publishes and distributes booklets dedicated to the most 
frequent respiratory diseases for patients. In 2017, a booklet 
on respiratory rehabilitation was published. On May 30th, 
2017, ČARO—GARD organized a meeting with MoH, and 
members for Senate, Czech Medical Society and Czech 
WHO Office. The meeting was dedicated to the 10th 
Anniversary of ČARO—GARD, No Tobacco Day and 
“Anti-smoking Law “in the Czech Republic. A special guest 
was Nikolai Khaltaev, who supported all activities of ČARO 
and presented increasing epidemiologic data of respiratory 
diseases in the world. ČARO supported the fight against 
smoking in restaurants. 
Other very interesting activities from other countries or 
regions were reported (e.g., Using e-Learning to promote 
correct inhaler use: Education for Health UK, and the 
Finland Allergy program). We can find all posters on the 
link https://gard-breathefreely.org/resources-poster/
Miscellaneous
Launch of GARD Lusophone Project (CPLP)
On 18th April, 2017, the Portuguese Institute of Tropical 
Medicine (IHMT) held a meeting on CRDs and tuberculosis 
in Lisbon. The invited delegates and participants included 
speakers from Angola, Brazil, Cape Verde, Mozambique, 
Portugal and three members of the GARD Ex-Com (Álvaro 
Cruz, José Rosado Pinto and Nils Billo). 
In the conclusion of this meeting, the heterogeneity of 
national situations with different realities was analyzed. A 
common strategic area was proposed to be implemented in 
terms of integrated patient centered care and priorities, bold 
policies and supportive systems, research and innovation 
projects and creation of a GARD common electronic 
platform in Portuguese, coordinated by IHMT. Finally, a 
GARD Lusophone project was decided to be launched.
The next steps were the establishment of a GARD 
Lusophone Study Group, contacts at country level with 
national MOHs, implementation of the CRD inclusion in 
national health programs as a priority and elaboration of an 
electronic platform with the IHMT-based secretariat. There 
was also the proposal for the GARD Lusophone project to be 
on the agenda of the Committee of the Portuguese Speaking 
Countries (CPLP) MoHs meeting in Brasilia, October 
2017. Early in October 2017, a Skype Conference was made 
involving the delegates of the five countries and the GARD 
Secretary (Nils Billo). On October 26, the MoHs of CPLP 
(Angola, Brazil, Cape Verde, East Timor, Guinea-Bissau, 
Mozambique, Portugal, and São Tomé e Principe) approved 
the GARD Lusophone project based on GARD-Brasilia 
(Brazil) under the proposal of IHMT (47-53). 
Studies on traffic related air pollution (TRAP) in several 
countries
TRAP has been known to be a major health hazard for 
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many years, but recent research has shown that it may have 
a greater impact on chronic disease onset than previously 
thought. TRAP is a major source of ozone-producing 
primary pollutants, including nitrogen oxides (NOx) and 
volatile organic compounds (VOCs). Ozone has been known 
to cause oxidative damage in humans, and chronic exposure 
has been shown to lead to the onset and exacerbation of 
several chronic respiratory conditions, as well as other 
cardiovascular and endocrine conditions. Through a series 
of literature reviews, studies on TRAP and ozone’s impacts 
on human health were designed and conducted for Brazil, 
Japan, the Netherlands, and Turkey. The analysis showed 
that though each country faces different air pollution 
problems, several important sources are common among 
all of the selected countries. The most important of these 
sources is TRAP from mobile sources, including cars, 
trucks, and cargo ships. Studies have shown that restrictions 
on these transport methods lead to significantly cleaner air 
quality and a reduction in chronic disease incidence and 
mortality. Significant investment in clean-energy public 
transportation could be the solution to reducing TRAP, and 
thus background ozone levels, in major cities (41,54-56).
GARD section in the Journal of Thoracic Disease (57)
Ever since August 2017, GARD has been collaborating with 
Journal of Thoracic Disease (JTD) on a featured section in 
this journal. The GARD section is a non-profiting, quick-
response platform to publish GARD activities at country, 
regional and global level, and to provide advocacy and 
awareness, at all levels from the community and the patient 
to health services and governments, aiming at universal 
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